Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic carcinoma, familial 1Pancreatic Intraductal Neoplasms 1Lung Carcinoma Metastatic in the Brain 1Head and Neck Neoplasms 1Glioblastoma 1

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Aminolevulinic Acid 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Ferrosoferric Oxide × Clear all
NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

OHSU Knight Cancer Institute

Phase 2 Terminated
52 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡